Doximity Inc SEC Filings

Doximity, Inc. reported an insider tax-withholding transaction by its Chief Executive Officer. On 11/15/2025, the CEO, who is also a director and 10% owner, had 8,005 shares of Class A Common Stock withheld by Doximity at a price of $49.62 per share. This withholding was done to cover tax obligations arising from the vesting of previously granted restricted stock units and was executed under a standing election by the company, rather than as a discretionary open-market trade by the executive. Following this transaction, the reporting person beneficially owned 2,241,053 shares of Doximity Class A Common Stock in direct ownership.

Doximity, Inc. (DOCS) director reported receiving 31,064 restricted stock units (RSUs) on November 15, 2025 under the company’s 2021 Stock Option and Incentive Plan. The RSUs vest in 10 equal quarterly installments after that date, contingent on the director’s continued service with the company at each vesting date. Each RSU converts into one share of Doximity Class A common stock at settlement, awarded at a stated price of $0 per share. Following this grant, the director beneficially owns 50,903 shares of Doximity Class A common stock in total.

Doximity, Inc. (DOCS) reported insider activity by its Chief Financial Officer. On 11/04/2025, the officer acquired 20,200 and 2,668 shares of Class A common stock, each labeled as a code C conversion from Class B following option exercises. The option exercises were at $4.12 and $2.21 per share, respectively.

Following these transactions, the officer beneficially owned 369,793 shares of Class A common stock, held directly. Footnotes state Class B shares are convertible into Class A on a one-for-one basis at the holder’s option, with automatic conversion upon certain events. The reported stock options carry expirations on 12/21/2030 and 09/28/2030, with vesting schedules as disclosed.

Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.

Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.

Doximity, Inc. filed an 8-K announcing it issued a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except as expressly referenced. The report was signed by Chief Financial Officer Anna Bryson.

Doximity (DOCS): Director Form 4 filing. On 11/03/2025, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, converted those 2,000 Class B shares into 2,000 Class A shares, and sold 2,000 Class A shares at $66.44 per share pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2024. Following these transactions, Class A Common Stock beneficially owned directly totaled 19,839 shares. The stock option was originally granted on June 10, 2020 and vests in 36 equal monthly installments starting March 27, 2020, with an expiration date of June 9, 2030.

FMR LLC8,777,627.56 shares of Doximity (DOCS) Class A common stock, representing 6.4%, with a date of event of 09/30/2025.

FMR reports sole voting power over 8,765,947.45 shares and sole dispositive power over 8,777,627.56 shares. Abigail P. Johnson reports sole dispositive power over 8,777,627.56 shares and no voting power. The filing certifies the holdings were acquired and are held in the ordinary course and not to change or influence control.

DOCS: A stockholder filed a Form 144 notice to sell 2,000 shares of common stock with an aggregate market value of $132,880. The filing lists Morgan Stanley Smith Barney as broker, an approximate sale date of November 3, 2025, and NYSE as the exchange.

The shares were acquired via a stock option exercise on November 3, 2025 for cash. Recent activity shows sales of 2,000 shares on October 1, 2025 for $140,020 and 2,000 shares on September 2, 2025 for $133,140. Shares outstanding were 136,400,248.

Doximity, Inc. (DOCS): A director reported multiple transactions on 10/10/2025. The insider exercised 5,000 stock options at an exercise price of $2.21, converted 5,000 shares of Class B Common Stock into Class A Common Stock, and sold 5,000 Class A shares at an average price of $70.84 pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2025.

Following the transactions, the insider reported 19,839 shares of Class A Common Stock held directly. The filing notes that each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder’s option, and also outlines additional automatic conversion conditions.